{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:42:03Z","timestamp":1785796923278,"version":"3.56.0"},"reference-count":115,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2024,1,2]]},"DOI":"10.1080\/14728214.2024.2303093","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T17:03:19Z","timestamp":1704474199000},"page":"5-17","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Review of phase 2\/3 trials in polymyalgia rheumatica and giant cell arteritis"],"prefix":"10.1080","volume":"29","author":[{"given":"Pratheeshaa","family":"Nageswaran","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Royal Free London NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, East Suffolk and North Essex Foundation Trust, Colchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Tahir","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Royal Free London NHS Trust, London, UK"},{"name":"Department of Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.2217\/ahe.11.50"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30155"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1214825"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23176"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13525"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102670"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37715"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24459"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew273"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra022694"},{"key":"e_1_3_3_12_1","unstructured":"Baseline data on patients enrolled in a randomized double-blind trial of Tocilizumab in giant cell arteritis [Internet]. ACR Meeting Abstracts. [cited 2023 Aug 21]. Available from: https:\/\/acrabstracts.org\/abstract\/baseline-data-on-patients-enrolled-in-a-randomized-double-blind-trial-of-tocilizumab-in-giant-cell-arteritis\/"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141347"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.623716"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.27.5.397"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.1.46"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.5444"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.142"},{"key":"e_1_3_3_19_1","unstructured":"Acharya S Musa R Polymyalgia Rheumatica. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Aug 14]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537274\/"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207492"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep303a"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.2.189"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-7-200410050-00005"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06263-3"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex459"},{"issue":"4","key":"e_1_3_3_26_1","first-page":"S86","article-title":"Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis","volume":"31","author":"Muratore F","year":"2013","unstructured":"Muratore F, Pipitone N, Hunder GG, et al. Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis. Clin Exp Rheumatol. 2013;31(4 Suppl 78):S86\u201392.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-015-0513-4"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.10-4-381"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215672"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22163"},{"issue":"6","key":"e_1_3_3_31_1","first-page":"1484","article-title":"A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients","volume":"27","author":"Chevalet P","year":"2000","unstructured":"Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000;27(6):1484\u20131491.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.872903"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000033"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev348"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0b013e318268aa9b"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39037"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(03)00228-8"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003210"},{"key":"e_1_3_3_39_1","unstructured":"University Hospital Caen. A randomized controled open label trial: comparison between two standardized corticosteroids tapering respectively short (North American) and Long (European) in giant cell arteritis [Internet]. Clinicaltrials.Gov; 2020 Oct [cited 2023 Oct 6]. Report No.: NCT04012905. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04012905"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161516"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23429"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-017-0052-8"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S228400"},{"key":"e_1_3_3_44_1","unstructured":"Overview | tocilizumab for treating giant cell arteritis | guidance | NICE [Internet]. NICE; 2018 [cited 2023 Aug 5]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta518"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkac037"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/29.6.456"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2011.13156"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613849"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1837-7"},{"key":"e_1_3_3_50_1","unstructured":"RoActemra 20mg\/ml concentrate for solution for infusion - summary of product characteristics (SmPC) - (emc) [Internet]. [cited 2023 Aug 13]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/6673\/smpc#gref"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00038-2"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab780"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab677"},{"key":"e_1_3_3_54_1","unstructured":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. [cited 2023 Aug 23]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.11388"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11388"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21984"},{"key":"e_1_3_3_57_1","unstructured":"Scenario: Management | Management | Giant cell arteritis | CKS | NICE [Internet]. [cited 2023 Oct 8]. Available from: https:\/\/cks.nice.org.uk\/topics\/giant-cell-arteritis\/management\/management\/"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00976-8"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23901"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab756"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102732"},{"key":"e_1_3_3_62_1","unstructured":"Brief report: In search of a candidate pathogen for giant cell arteritis: Sequencing\u2010based characterization of the giant cell arteritis microbiome. [cited 2023 Aug 21]. Available from: https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.38631"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.05.021"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.789172"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.161"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32833ee946"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00754.x"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65175-9"},{"key":"e_1_3_3_69_1","unstructured":"Serum interleukin\u20106 receptor in polymyalgia rheumatica: a potential marker of relapse\/recurrence risk. [cited 2023 Aug 15]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.23924"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-7-199410010-00003"},{"key":"e_1_3_3_71_1","unstructured":"Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. [cited 2023 Aug 21]. Available from: https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.38625"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3140"},{"key":"e_1_3_3_73_1","doi-asserted-by":"crossref","unstructured":"Salvarani C Macchioni P Manzini C et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica. Ann Intern Med [Internet]. 2007 May 1 [cited 2023 Aug 31]. Available from: https:\/\/www.acpjournals.org\/doi\/10.7326\/0003-4819-146-9-200705010-00005","DOI":"10.7326\/0003-4819-146-9-200705010-00005"},{"key":"e_1_3_3_74_1","unstructured":"Novartis Pharmaceuticals. A 2-week single-blind randomized 3-arm proof of concept study of the effects of AIN457 (anti-IL17 antibody) ACZ885 (Canakinumab anti-IL1b antibody) or corticosteroids in patients with polymyalgia rheumatica followed by an open label phase to assess safety and long term efficacy [Internet]. Clinicaltrials.Gov; 2021 Aug [cited 2023 Sep 1]. Report No.: NCT01364389. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01364389"},{"key":"e_1_3_3_75_1","unstructured":"Novartis Pharmaceuticals. A randomized parallel-group double-blind placebo-controlled multicenter phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo in combination with a Glucocorticoid Taper Regimen in patients with polymyalgia rheumatica (PMR) [Internet]. Clinicaltrials.Gov. 2023 Oct [cited 2023 Oct 13]. Report No.: NCT05767034. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05767034"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39740"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208742"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.15459"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221126"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303452"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223562"},{"key":"e_1_3_3_82_1","unstructured":"University Hospital Brest. BAriCitinib healing effect in earLy pOlymyalgia rheumatica (BACHELOR study) [Internet]. Clinicaltrials.Gov; 2022 Jan [cited 2023 Oct 13]. Report No.: NCT04027101. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04027101"},{"key":"e_1_3_3_83_1","unstructured":"Sint Maartenskliniek. Rituximab effect on decreasing glucocorticoid exposition in polymyalgia rheumatica patients experiencing a PMR relapse [Internet]. Clinicaltrials.Gov; 2023 May [cited 2023 Oct 13]. Report No.: NCT05533164. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05533164"},{"key":"e_1_3_3_84_1","unstructured":"University Hospital Brest. To demonstrate the ability of abatacept in comparison to placebo to obtain a low disease activity [PMR-AS (CRP) lower or equal to 10] without GCs (prednisone or prednisolone) at week 12 in early onset PMR patients. [Internet]. Clinicaltrials.Gov; 2022 May [cited 2023 Oct 13]. Report No.: NCT03632187. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03632187"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40044"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24632"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/l0hd9v"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220873"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221865"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030423"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac203"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1187584"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.04.004"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24200"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001084"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201836"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205261"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00101-7"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac416"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex507"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2013.06.004"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab280"},{"key":"e_1_3_3_103_1","unstructured":"University Hospital Caen. Randomized controlled double-blind study of Anakinra against placebo in addition to steroids in giant cell arteritis [Internet]. Clinicaltrials.Gov; 2020 Feb [cited 2023 Oct 6]. Report No.: NCT02902731. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02902731"},{"key":"e_1_3_3_104_1","unstructured":"Janssen Research & Development LLC. A phase 2 multicenter randomized placebo-controlled double-blind proof-of-concept study to evaluate guselkumab for the treatment of participants with new-onset or relapsing giant cell arteritis [Internet]. Clinicaltrials.Gov; 2023 Sep [cited 2023 Oct 6]. Report No.: NCT04633447. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04633447"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203586"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-9-200705010-00004"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0684-0"},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.036533"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000265"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000100"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-018-1269-5"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131254"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab179"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem379"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes153"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X13512256"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2024.2303093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T16:56:47Z","timestamp":1727197007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2024.2303093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"alternative-id":["10.1080\/14728214.2024.2303093"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2024.2303093","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}